Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.
about
Substrate stiffness influences phenotype and function of human antigen-presenting dendritic cells.Trial Watch: Adoptively transferred cells for anticancer immunotherapy.Trial watch: Dendritic cell-based anticancer immunotherapy.Multiple Antigen Stimulating Cellular Therapy (MASCT) For Hepatocellular Carcinoma After Curative Treatment: A Retrospective Study.Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
P2860
Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adjuvant dendritic cell vaccin ...... f stage III melanoma patients.
@en
Adjuvant dendritic cell vaccin ...... f stage III melanoma patients.
@nl
type
label
Adjuvant dendritic cell vaccin ...... f stage III melanoma patients.
@en
Adjuvant dendritic cell vaccin ...... f stage III melanoma patients.
@nl
prefLabel
Adjuvant dendritic cell vaccin ...... f stage III melanoma patients.
@en
Adjuvant dendritic cell vaccin ...... f stage III melanoma patients.
@nl
P2093
P2860
P50
P1433
P1476
Adjuvant dendritic cell vaccin ...... of stage III melanoma patients
@en
P2093
Annemiek J de Boer
Carl G Figdor
Cornelis J A Punt
Erik H J G Aarntzen
Gerty Schreibelt
Harm Westdorp
Jeanne M Pots
Johannes H W de Wilt
Johannes J Bonenkamp
Mandy W M M van de Rakt
P2860
P304
P356
10.1080/2162402X.2016.1191732
P577
2016-05-31T00:00:00Z